Supplementary Figure S1. Schematic representation and establishment of the B-cell lymphoma PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Year: 2023
Type: supplementary-materials
Abstract: A, Schematic describing the primary B-cell lymphoma PDX SCID/NSG-hu mouse model. Six-to 8-week-old male NSG or CB-17 SCID mice were implanted with human fetal bone. Approximately 4 to 6 weeks following bone implantation, one injection of 5 Ã- 106 patient tumor cells were administered directly into the human fetal bone chip as the first generation (G1). The levels of circulating human β2M in mouse serum were used to monitor tumor engraftment and growth in G1 mice. Once tumor burden was detected, the pieces of tumor with bone chip were subcutaneously transplanted into NSG mice as the second generation (G2). After G2, the consistent growths of tumor in NSG mice were acquired. Single-agent targeted therapy, drug-resistant treatment, or combination therapy, were administered in the indicated generations. B, Human β2M reflected the tumor burdens of 16 B-cell lymphomas in PDX-G1 mice. After 3-4 weeks of tumor inoculation, mouse sera were collected from the peripheral blood of tail vein, and the level of human β2M was determined by ELISA.
Authors: Leo Zhang, Krystle Nomie, Hui Zhang, Taylor Bell, Lan Pham, Sabah Kadri, Jeremy Segal, Shaoying Li, Shouhao Zhou, David Santos, Shawana Richard, Shruti Sharma, Wendy Chen, Onyekachukwu Oriabure, Yang Liu, Shengjian Huang, Hui Guo, Zhihong Chen, Wenjing Tao, Carrie Li, Jack Wang, Bingliang Fang, Jacqueline Wang, Lei Li, Maria Badillo, Makhdum Ahmed, Selvi Thirumurthi, Steven Y. Huang, Yiping Shao, Laura Lam, Qing Yi, Y. Lynn Wang, Michael Wang
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362432574